Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-8722

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas ; volume:10 ; number:1 ; day:19 ; month:6 ; year:2017 ; pages:1-10 ; date:12.2017
Journal of hematology & oncology ; 10, Heft 1 (19.6.2017), 1-10, 12.2017

Keyword: Krebs
Onkologie

Creator: Laroche-Clary, Audrey

Contributor: Chaire, Vanessa
Algéo, Marie-Paule
Derieppe, Marie-Alix
Loarer, François L.
Italiano, Antoine
SpringerLink (Online service)

DOI: 10.1186/s13045-017-0482-3

URN: urn:nbn:de:1111-201709104746

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:25 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Laroche-Clary, Audrey
Chaire, Vanessa
Algéo, Marie-Paule
Derieppe, Marie-Alix
Loarer, François L.
Italiano, Antoine
SpringerLink (Online service)

Other Objects (12)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

The role of targeting CDK4/6 in cancer immunotherapy

Targeting MDM2, the antagonist of the tumor suppressor p53

CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

MiR-181b sensitizes glioma cells to teniposide by targeting MDM2

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

The role of targeting CDK4/6 in cancer immunotherapy

Targeting MDM2, the antagonist of the tumor suppressor p53

CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

MiR-181b sensitizes glioma cells to teniposide by targeting MDM2

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

The role of targeting CDK4/6 in cancer immunotherapy

Targeting MDM2, the antagonist of the tumor suppressor p53

CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

MiR-181b sensitizes glioma cells to teniposide by targeting MDM2

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

The role of targeting CDK4/6 in cancer immunotherapy

Targeting MDM2, the antagonist of the tumor suppressor p53

CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

MiR-181b sensitizes glioma cells to teniposide by targeting MDM2

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

The role of targeting CDK4/6 in cancer immunotherapy

Targeting MDM2, the antagonist of the tumor suppressor p53

CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

MiR-181b sensitizes glioma cells to teniposide by targeting MDM2

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

The role of targeting CDK4/6 in cancer immunotherapy

Targeting MDM2, the antagonist of the tumor suppressor p53

CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

MiR-181b sensitizes glioma cells to teniposide by targeting MDM2

Related objects

Reset password